Develops and commercializes therapeutic products for rare disorders. Now — the numbers.
That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.
This is an established company with proven profits.
Average growth of 18% a year over the last 4 years. Every year shown ended in profit.
If every debt were paid off today, $437.4M would still be left in the vault — a solid cushion for hard times.
Over the last 4 years, sales grew about 18% a year on average.
There is $3.0B in the vault; even if every debt were paid off, $437.4M would remain.
It met or beat analyst expectations in 8 of the last 8 quarters — consistency is a promise kept.
Our checks did not surface a specific risk to flag here. That is not the same as there being none.
We don’t have a report card for this stock yet — the data isn’t mature enough to grade. No grade is information too: it means the evidence is thin.
One-line summary: few numbers, an untested story. Keep watching.
Not covered, because the filings we hold do not carry it: the price history.